CytoMed Therapeutics Limited (GDTC) has released an update.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
CytoMed Therapeutics Limited announces a pilot program offering free cell banking to its loyal shareholders, enabling them to store their peripheral blood mononuclear cells (PBMCs) for future therapeutic uses. The initiative, set to launch on June 1, 2024, aims to support the development of personalized cellular therapies for cancer and age-related diseases. Shareholders meeting specific criteria can bank their cells, providing a source for potential future regenerative medicine and disease treatments.
For further insights into GDTC stock, check out TipRanks’ Stock Analysis page.
